impella family medical devices used temporary ventricular support patients depressed heart function versions device provide left heart support forms mechanical circulatory support including ecmo device approved use highrisk percutaneous coronary intervention pci cardiogenic shock following heart attack open heart surgery placed peripheral peripheral artery pumps blood left right heart via ascending aorta pulmonary artery impella technology acquired abiomed march impella series includes impella impella impella cp impella impella device alternative percutaneous mechanical circulatory support utilized bridge recovery used alone tandem sets utilizes concept magnetic levitationclarification needed reduce moving parts absolute minimum thus reducing anticoagulation requirements cardiogenic shock addressed many devices notably intraaortic balloon pump iabp technology deployed impella device similarly alters fundamental characteristics human circulatory system propeller accelerated give respite acutely injured myocardium circulatory system transitions pulsatile mechanism continuous flow cellular response cardiogenic shock poorly described either method counterpulsation continuous flow control directional flow device magnetic vectors investigation addressing right versus leftsided heart failure transseptal intervention addressing physiologic mismatch perfusion left rightsided heart failure experimental statuscitation needed however recent studies point significantly greater inhospital risks major bleeding death adverse events patients supported impella devices compared managed propensitymatched comparison patients receiving mechanical circulatory support mcs myocardial shock saw nearly onethird excess mortality almost doubling risk major bleeding inhospital endpoints use impella compared iabp impella may provide results similar venoarterial extracorporeal life support patients acute myocardial infarction complicated cardiogenic shock haemodynamic support impella device significant effect thirtyday mortality compared overall outcomes population regardless mcs device significantly worse patients approval impellaclarification needed among hospitals using impella using significantly worse outcomes impella using leastcitation needed potential complications related use impella device relatedclarification needed peripheral vascular distal thrombus formation subsequent strokes common complications reported bleeding requiring transfusion vascular access complications infection haemolysis vascular complications requiring surgical repair limb ischaemia bleeding requiring surgical intervention valvular complications included aortic mitral valve injury mitral valve impella heart pumps percutaneous microaxial pumps act mechanical circulatory support devices patients need hemodynamic pumps mounted support catheters typically inserted femoral artery although axillary subclavian artery approaches impella device generational extension intra aortic balloon pump iabp addressing cardiogenic shock tech allowed single moving piece floated magnetically steered mechanisms deploy archimedes pump north aortic valve purports reduce preload afterload tech apparently also deployed pulmonary pulmonic valve gate right sided heart failure designed provide hemodynamic support patients heart unable produce sufficient cardiac output impella heart pumps supply one five liters per minute blood physiological consequences leftsided support threefold first unloads left ventricle reducing left ventricular enddiastolic volume pressure thereby decreasing ventricular wall stress work myocardial oxygen second increases mean arterial pressure diastolic pressure cardiac output improving cardiac power output cardiac combined effects wall stress perfusion pressure especially diastolic pressure augment coronary lastly augmented cardiac output forward flow left ventricle decreases pulmonary capillary wedge pressure reduces right ventricular impella approved mechanical circulatory support largescale realworld data use lacking june impella heart pump received fda partial circulatory support periods six hours cardiac procedures requiring cardiopulmonary bypass march received fda premarket approval elective urgent highrisk percutaneous intervention december premarket approval expanded include impella cp heart april impella impella ld heart pumps received clearance circulatory support periods six hours cardiac procedures requiring cardiopulmonary july automated impella controller received fda clearance use trained healthcare professionals healthcare facilities medical january impella rp granted humanitarian device exemption provide circulatory assistance patients right heart february fda approved sale impella ventricular support deaths strokes data base overall shot impella gained regulatory approval compared earlier years mortality went strokes httpsenwikipediaorgwikiimpella